Skip to main content
. 2022 May 18;10(5):1159. doi: 10.3390/biomedicines10051159

Figure 3.

Figure 3

The effect of 12 weeks of KD on systemic inflammation and atherosclerotic plaque burden. Plasma concentrations of (A) interleukin 6 (IL-6) and (B) tumor necrosis factor α (TNF-α). (C) Ex vivo 14T-MRI volumetric assessment of total atheroma. Data shown are the mean ± SEM, n = 4–8/group. ***, p < 0.001, KD versus control.